Dr. Nedd is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3230 Eagle Park Dr Ne
Suite 101
Grand Rapids, MI 49525Phone+1 616-954-0600Fax+1 616-954-1675
Summary
- Dr. Khan Nedd is an internist in Grand Rapids, MI and is affiliated with multiple hospitals in the area, including Spectrum Health - Butterworth Hospital and Mercy Health Saint Mary's. He received his medical degree from Michigan State University College of Human Medicine and has been in practice 31 years. He specializes in hospital medicine/hospitalist.
Education & Training
Corewell Health – Grand Rapids/Michigan State UniversityResidency, Internal Medicine, 1986 - 1990
Michigan State University College of Human MedicineClass of 1986
Intermountain Medical CenterFellowship, Process Improvement ATP- UCSFLeadership
Certifications & Licensure
OH State Medical License 2024 - 2026
MI State Medical License 1987 - 2025
WI State Medical License 2024 - 2025
Clinical Trials
- Treatment Protocol of Replagal for Patients With Fabry Disease
- Open-Label Phase 3 Long-Term Safety Study of Migalastat Start of enrollment: 2011 Oct 14
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease Start of enrollment: 2015 Mar 14
Publications & Presentations
PubMed
- 39 citationsSafety and efficacy of alternative alglucosidase alfa regimens in Pompe diseaseLaura E. Case, Carl Bjartmar, Claire Morgan, Robin Casey, Joel Charrow
Neuromuscular Disorders. 2015-04-01 - 3 citationsImpact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Pati...Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel
Advances in Therapy. 2022-05-01 - 39 citationsLong-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.Ulla Feldt-Rasmussen, Derralynn Hughes, Gere Sunder-Plassmann, Suma P. Shankar, Khan Nedd
Molecular Genetics and Metabolism. 2020-09-01
Press Mentions
Protalix’s Phase III Asset for Fabry Could Struggle to Demonstrate Superiority over Fabrazyme but Immunogenicity Benefits Support Regulatory Chances, Experts SayFebruary 5th, 2021
Answer Health Goes Live with Lightbeam Health SolutionsJune 12th, 2019
Boyne Acquires Infusion Associates ManagementDecember 17th, 2018- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
